desidustat
Small moleculeexperimental
Desidustat is a drug for the treatment of anemia of chronic kidney disease. This drug with the brand name Oxemia is discovered and developed by Zydus Life Sciences. — Wikipedia
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
1
Earliest trial started Jul 20, 2019 (NCT04012957)
Timeline
Indications
Approved for
Mechanism of action
- Egl nine homolog 1ANTAGONIST
EGLN1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O- Mol. weight
- 332.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDesidustat ↗
- ChEMBLCHEMBL4650314 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05515367 | Phase 4 | Oct 4, 2022 | Zydus Discovery DMCC |
| NCT04667533 | Phase 1 | Nov 11, 2020 | Cadila Healthcare |
| NCT04463602 | Phase 2 | Jul 25, 2020 | Cadila Healthcare |
| NCT04215120 | Phase 3 | Dec 12, 2019 | Cadila Healthcare |
| NCT04012957 | Phase 3 | Jul 20, 2019 | Cadila Healthcare |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cadila Healthcare | For profit | 4 | 4 | 3 | 2019 |
| Zydus Discovery DMCC | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1